Cathie Wood could use a bit o'
REVANCE (chin area)
GBA Presents: RADIO SAVANT-!
- Thread starter stonedinvestor
- Start date
Cathie Wood could use a bit o'
REVANCE (chin area)
I'm liking the Revance play here for a few reasons...
Back in March there was a general feeling that this stk was a $30-$40stk// allPT's were in there that was the last reporting period.
Then we had good news about a Q1 launch for Daxxify...(I have to look it up)
Ok then layered upon that we have Revance's strategy to prioritize prestige accounts that are likely to be early adopters should help shield it from potential macro headwinds in 2023.
alright--> stock moves to $37 (top end of PT range)
Reports and immediately gets two houses throwing out PT's of $50 & $48.
TOP IDEA RVNC-
ALSO
DAR- (FROM YEST)
Back in March there was a general feeling that this stk was a $30-$40stk// allPT's were in there that was the last reporting period.
Then we had good news about a Q1 launch for Daxxify...(I have to look it up)
Ok then layered upon that we have Revance's strategy to prioritize prestige accounts that are likely to be early adopters should help shield it from potential macro headwinds in 2023.
alright--> stock moves to $37 (top end of PT range)
Reports and immediately gets two houses throwing out PT's of $50 & $48.
TOP IDEA RVNC-
ALSO
DAR- (FROM YEST)
OH WAIT OF COURSE-- THIS IS THE BOTOX-LIKE IDEA THAT DOESN'T FREEZE YOUR FACE!!!
DUH
F.D.A. OKs Daxxify, an Anti-Wrinkle Drug and Botox Competitor
The treatment lasts for six months in half of its users, company studies showed, representing the first major advance in facial injections in decades.
DUH
F.D.A. OKs Daxxify, an Anti-Wrinkle Drug and Botox Competitor
The treatment lasts for six months in half of its users, company studies showed, representing the first major advance in facial injections in decades.
We need to go through what her holdings are in her ARK robotics or whatever it's called.
Cathie Wood could use a bit o'
REVANCE (chin area)
I've been saying this for years now, but I want the company that will revolutionize fast food places like BK and MCD. I've said it a hundred times, there's no reason a MCD couldn't be 80% automated. Robots can cook hamburgers, fill cups, etc.
Revance Therapeutics, the maker of the new treatment, Daxxify, announced the approval on Thursday morning, saying its effects — by injection into the face along worry lines — lasted longer than other products on the market.
Like AbbVie’s Botox, the new treatment is a neuromuscular blocking agent that essentially freezes wrinkles. It is also a botulinum toxin, which, when used as directed, is not detected in the patient’s bloodstream.
In studies submitted to the F.D.A., the treatment far exceeded the effect of a placebo, with about 80 percent of the treatment providers seeing no or mild facial lines at four months after injection and about half seeing the effect through six months.
One of the Revance studies submitted to the F.D.A. for the aesthetic use of Daxxify found that users experienced more side effects than those getting a placebo; six percent got a headache and two percent developed a drooping eyelid.
The drug had a rocky road to approval. Revance, based in Nashville, initially hoped for approval in November 2020, but the F.D.A. postponed an inspection of the manufacturing site because of the travel restrictions imposed during the coronavirus pandemic, according to Dr. Prasad.
In June 2021, the F.D.A. conducted the inspection and discovered problems with the company’s quality control process and working cell bank, or a collection of cells that contains the drug’s active ingredient, agency records show. Mr. Foley said those concerns were resolved once the company got a new working cell bank in operation.
Like AbbVie’s Botox, the new treatment is a neuromuscular blocking agent that essentially freezes wrinkles. It is also a botulinum toxin, which, when used as directed, is not detected in the patient’s bloodstream.
In studies submitted to the F.D.A., the treatment far exceeded the effect of a placebo, with about 80 percent of the treatment providers seeing no or mild facial lines at four months after injection and about half seeing the effect through six months.
One of the Revance studies submitted to the F.D.A. for the aesthetic use of Daxxify found that users experienced more side effects than those getting a placebo; six percent got a headache and two percent developed a drooping eyelid.
The drug had a rocky road to approval. Revance, based in Nashville, initially hoped for approval in November 2020, but the F.D.A. postponed an inspection of the manufacturing site because of the travel restrictions imposed during the coronavirus pandemic, according to Dr. Prasad.
In June 2021, the F.D.A. conducted the inspection and discovered problems with the company’s quality control process and working cell bank, or a collection of cells that contains the drug’s active ingredient, agency records show. Mr. Foley said those concerns were resolved once the company got a new working cell bank in operation.
Why RHA by Revance is the best filler | RHA in San Diego
Changes Plastic Surgery & Spa
Don't want the frozen look of Botox or the stiffness of other dermal fillers?No problem. As we know, RHA® fillers work seamlessly with facial movements, ...
Super smart marketing.. " designer filler " hard to get... only for you know... people with money who envy celebrity culture of which there are many!!!!!
https://351face.com/revance-designer-fillers/
Revance Therapeutics, Inc. (RVNC)- Oh yea we scoop this!
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
37.61+1.01(+2.76%)
At close: 04:00PM EDT
34.11-3.50(-9.31%)<------------
Pre-Market:08:02AM EDT
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
37.61+1.01(+2.76%)
At close: 04:00PM EDT
34.11-3.50(-9.31%)<------------
Pre-Market:08:02AM EDT
Revance Reports First Quarter 2023 Financial Results, Provides Corporate Update
Tue, May 9, 2023, 4:05 PM EDT
In this article:
- RVNC
Watchlist
Pattern
Bullish
-Q1 total revenue of $49.3 million, a YoY increase of 95.3%.
-Q1 RHA® Collection revenue of $30.3 million, a YOY increase of 45.3%.
-Q1 DAXXIFY® revenue of $15.4 million, driven by PrevU and March launch.
-FDA approves Ajinomoto Biopharma Services, Revance’s contract manufacturer for DAXXIFY®.
-Fosun Pharma’s BLA submission for DaxibotulinumtoxinA for Injection for glabellar lines accepted for review by China’s National Medical Products Administration (NMPA).
-Conference call and webcast today at 4:30 p.m. ET.<---------
Algos holding AFRM at $11.50.
This one will be fun today.
Like I wrote last night, it might just pull a C3AI type run before it crashes back to what it's really worth.
As I pointed out yesterday:
This one will be fun today.
Like I wrote last night, it might just pull a C3AI type run before it crashes back to what it's really worth.
As I pointed out yesterday:
I'm going to have to buy this with the HF. So it will be a bigger purchase. This is what happens when you have a blow up (paypal) I'm ducking big Pete (plus all the RAIN pressure) and that closes off a buy ability for me right now. He has three of my six accounts.